Marshall Wace LLP Sells 284,246 Shares of Embecta Corp. (NASDAQ:EMBC)

Marshall Wace LLP decreased its position in shares of Embecta Corp. (NASDAQ:EMBC - Free Report) by 77.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 83,789 shares of the company's stock after selling 284,246 shares during the quarter. Marshall Wace LLP owned approximately 0.14% of Embecta worth $1,730,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Garden State Investment Advisory Services LLC bought a new stake in shares of Embecta during the 3rd quarter valued at $438,000. Barclays PLC increased its holdings in Embecta by 41.1% in the third quarter. Barclays PLC now owns 97,930 shares of the company's stock valued at $1,381,000 after purchasing an additional 28,523 shares during the last quarter. Oppenheimer Asset Management Inc. acquired a new position in Embecta in the fourth quarter valued at about $209,000. Bank of New York Mellon Corp boosted its holdings in Embecta by 0.7% during the fourth quarter. Bank of New York Mellon Corp now owns 685,493 shares of the company's stock worth $14,155,000 after buying an additional 4,769 shares during the last quarter. Finally, Amundi grew its position in shares of Embecta by 161.2% during the 4th quarter. Amundi now owns 32,287 shares of the company's stock worth $655,000 after buying an additional 19,925 shares during the period. 93.83% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Mizuho began coverage on shares of Embecta in a research note on Thursday, April 10th. They set a "neutral" rating and a $15.00 price objective on the stock.

Embecta Price Performance

Shares of Embecta stock traded up $0.45 during trading hours on Friday, hitting $12.73. The company's stock had a trading volume of 261,870 shares, compared to its average volume of 455,272. The company has a market capitalization of $740.05 million, a PE ratio of 12.73, a price-to-earnings-growth ratio of 0.78 and a beta of 1.23. The stock has a 50 day moving average of $12.53 and a 200 day moving average of $15.80. Embecta Corp. has a 12 month low of $10.15 and a 12 month high of $21.48.

Embecta (NASDAQ:EMBC - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $0.65 EPS for the quarter, topping the consensus estimate of $0.45 by $0.20. Embecta had a net margin of 5.25% and a negative return on equity of 19.22%. Equities analysts expect that Embecta Corp. will post 2.85 EPS for the current year.

Embecta Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 14th. Shareholders of record on Friday, February 28th were issued a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 4.71%. The ex-dividend date was Friday, February 28th. Embecta's dividend payout ratio (DPR) is presently 60.00%.

Insider Buying and Selling at Embecta

In other news, Director Milton Mayo Morris sold 3,100 shares of the business's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $16.38, for a total value of $50,778.00. Following the sale, the director now owns 36,133 shares of the company's stock, valued at $591,858.54. The trade was a 7.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.42% of the company's stock.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.